Altimmune Stock (NASDAQ:ALT)
Previous Close
$6.93
52W Range
$5.28 - $14.84
50D Avg
$7.92
200D Avg
$7.17
Market Cap
$494.32M
Avg Vol (3M)
$3.30M
Beta
0.07
Div Yield
-
ALT Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HEPA | Hepion Pharmaceuticals, Inc. |
| INMB | INmune Bio, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| ATHA | Athira Pharma, Inc. |
| FBIO | Fortress Biotech, Inc. |
| VSTM | Verastem, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| ACAD | ACADIA Pharmaceuticals Inc. |
| CGTX | Cognition Therapeutics, Inc. |
| AVXL | Anavex Life Sciences Corp. |
| CABA | Cabaletta Bio, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| ARDX | Ardelyx, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| INZY | Inozyme Pharma, Inc. |
| BIVI | BioVie Inc. |
| SAVA | Cassava Sciences, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| ZURA | Zura Bio Limited |